Effectiveness of several external beam radiotherapy schedules for palliation of esophageal cancer

Natasja R. Walterbos a, Marta Fiocco b,c, Karen J. Neelis a, Yvette M. van der Linden a,d, Alexandra M.J. Langers e, Marije Slingerland f, Wobbe O. de Steur g, Femke P. Peters a, Irene M. Lips a,⇑

a Department of Radiation Oncology, Leiden University Medical Center, Postzone K0-P, P.O. Box 9600, 2300 RC Leiden, The Netherlands
b Department of Biomedical Data Science, Section Medical Statistics, Leiden University Medical Center, Postzone S5-P, P.O. Box 9600, 2300 RC Leiden, The Netherlands
c Center of Expertise Palliative Care, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands

d Mathematical Institute, Leiden University, P.O. Box 9512, 2300 RA Leiden, The Netherlands

*e Corresponding author at: Department of Radiation Oncology, Leiden University Medical Center, Postzone K0-P, Postbus 9600, 2300 RC Leiden, The Netherlands.

E-mail addresses: n.r.walterbos@lumc.nl (N.R. Walterbos), m.fiocco@lumc.nl (M. Fiocco), k.j.neelis@lumc.nl (K.J. Neelis), ymvanderlinden@lumc.nl (Y.M. van der Linden), a.m.j.langers@lumc.nl (A.M.J. Langers), m.slingerland@lumc.nl (M. Slingerland), w.o.de_steur@lumc.nl (W.O. de Steur), f.p.peters@lumc.nl (F.P. Peters), i.m.lips@lumc.nl (I.M. Lips).

https://doi.org/10.1016/j.ctro.2019.04.017

© 2019 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Esophageal cancer is the eighth most common cancer worldwide. Every year 400,000 people die from this disease, making it the sixth most common cause of death in the world [1]. In the Netherlands, the overall 5-year survival is approximately 19%, with most patients presenting at an advanced stage [2]. For these patients, palliative treatment often is the only option. Dysphagia is an important symptom, found in >70% of patients with esophageal cancer [3]. Since swallowing and eating problems have a large impact on the quality of life of patients, the most important aim of palliation is to relieve dysphagia symptoms.

Treatment options used for the palliation of dysphagia include local interventions such as stent placement [4], intraluminal brachytherapy (ILBT) [4–6], external beam radiotherapy (EBRT)
[7–17], and systemic treatment with chemotherapy, or even, combined chemoradiation [18,19]. A randomised trial [4] compared stent placement with ILBT for the treatment of incurable esophageal cancer. Stent placement gives more rapid improvement of dysphagia, but with shorter duration than ILBT, and is advised when life expectancy is less than three months. When long-term relief of dysphagia is desirable because of a longer life expectancy, ILBT or EBRT is more suitable [20]. In the Netherlands, palliative treatment of incurable esophageal cancer varies widely. Opstelten et al. reported that choice for treatment is not only related to patient and disease characteristics, but to hospital of diagnosis as well, suggesting a lack of therapeutic guidance [21]. Despite the evidence supporting ILBT [5], EBRT is generally more often applied [21].

Only a few studies have examined the effect of EBRT alone, using a great variety of radiotherapy schedules [7,9,13–16]. Consequently, the optimal EBRT schedule for symptom control is still unknown. The aim of this retrospective study was to evaluate three EBRT schedules for symptom control and to investigate possible prognostic factors associated with second intervention and overall survival (OS).

2. Material and methods

2.1. Patient selection

We conducted a retrospective analysis of consecutive patients with cancer of the esophagus treated with palliative intent at the department of Radiotherapy of the Leiden University Medical Center in Leiden, the Netherlands. Patients were included when they received their first radiotherapy treatment with palliative intent between January 2009 and December 2015. Medical files were screened for data collection. The study protocol was approved by the Medical Ethical Committee of the Leiden University Medical Center, the Netherlands. Due to the retrospective aspect of the study, Dutch regulations do not require to obtain informed consent.

2.2. Data collection

Recorded pretreatment variables were age; sex; Karnofsky performance status (KPS) (if not registered, estimated according to the description of performance status within the patient chart or recorded as unknown if no interpretation was possible); comorbidity (according to the Adult Comorbidity Evaluation-27 [22]); dysphagia score (as stated by Knyrim [23]); weight loss; pain; hematemesis; other symptoms; primary or recurrent presentation; need for tube feeding; tumour location (according to the AJCC Cancer Staging Manual [24]); tumour length (if the tumour length on endoscopy was not reported, the tumour length on CT scan was used instead); histological type; TNM stage (according to the 7th edition [25]; based on available imaging, such as endoscopy, ultrasound of the neck, CT scan and/or a whole body PET-CT scan); and indication(s) for palliative treatment (irresectable tumour, metastasis, performance status, patient preference or other). For both weight loss and tumour length, patients were divided into two categories based on the median. Follow-up was generally done at three to six weeks after treatment and continued according to the individual needs of the patient. Measured outcomes were clinical response, second intervention (repeat EBRT, ILBT and/or stent), acute toxicity and OS. Clinical response was defined as subjective improvement of symptoms, such as relief of pain, reduction of esophageal bleeding or improvement of dysphagia. The clinical response was interpreted from the medical files by the first author and, in case of doubt, reviewed by the last author. Time to second intervention was calculated from start of treatment to start of second intervention. Acute toxicity was defined as adverse effects reported in the patient chart during and within 6 weeks after treatment and was graded using the U.S. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [26]. OS was calculated from start of radiotherapy to death from any cause or last confirmed date of survival. When a patient was lost to follow-up, the municipal personal records database and general practitioner were consulted to obtain information about survival status.

2.3. External beam radiotherapy

Treatment schedules of 20 Gy in 5 fractions, 30 Gy in 10 fractions or 39 Gy in 13 fractions were used. In the departmental protocol, choice for any of the treatment schedules was based on expected survival, performance score, metastatic status, and patient preference. Treatment schedule was suggested by the responsible physician and approved by the department at daily team meetings. Patients were treated with one fraction a day, 4 days a week. Patients receiving 24 Gy in 6 fractions were included in the 20 Gy group, since we don’t expect it to have a major impact on the outcomes in accordance with literature on palliative radiotherapy for bone metastases (27,28).

A CT scan was performed for planning of the EBRT. The gross tumour volume (GTV) consisted of the tumour and nearby pathological lymph nodes. The clinical target volume (CTV) was formed by the GTV with a 1.0 cm margin in all directions, excluding other organs. For the planning target volume (PTV), the CTV was expanded with a 1.0 cm margin in all directions. A 2 or 4-field planning was used.

2.4. Statistical analysis

Recorded variables were reported with descriptive statistics. Chi-square test was used to test for significant differences between categorical baseline variables between groups based on the different treatment schedules.

OS was estimated with Kaplan-Meier’s methodology, using log-rank to test for significant difference between the treatment schedules. A Cox regression model was used to study the association between prognostic factors and OS. We selected possible prognostic factors based on clinical relevance and previous literature [17,29,30].

A competing risk model with death as competing event was employed to estimate the cumulative incidence of second intervention. To estimate the effect of prognostic factors on time to second intervention, a multivariate regression Cox model was fitted. Results are reported as cause specific hazard ratio along with 95% confidence interval [31].

Statistical analysis was performed using IBM SPSS software version 23, with a level of significance p value <0.05, unless otherwise mentioned. All analysis concerning the competing risk model were performed in R environment with the mstate library [32].

3. Results

218 patients were treated with radiotherapy with palliative intent between January 2009 and December 2015. Nine patients were excluded from analysis due to receiving ILBT (N = 4), ILBT in combination with EBRT (N = 2), or a deviant palliative EBRT schedule (two patients with a single dose of 6 or 8 Gy and one patient with 30 Gy in 10 fractions followed by a boost of 15 Gy in 5 fractions). Four patients were excluded because a stent was placed before starting with EBRT. The remaining 205 patients were
Table 1
Baseline characteristics.

| Characteristics | All patients (N = 205) | 20 Gy EBRT (N = 63) | 30 Gy EBRT (N = 77) | 39 Gy EBRT (N = 65) | P value |
|-----------------|------------------------|---------------------|---------------------|---------------------|---------|
| Gender          |                        |                     |                     |                     |         |
| Male            | 146 (71.2)             | 48 (76.2)           | 58 (75.3)           | 40 (61.5)           | 0.11    |
| Female          | 59 (28.8)              | 15 (23.8)           | 19 (24.7)           | 25 (38.5)           |         |
| Age             |                        |                     |                     |                     |         |
| ≤70             | 90 (43.9)              | 33 (52.4)           | 40 (51.9)           | 17 (26.2)           | <0.01   |
| >70             | 115 (56.1)             | 30 (47.6)           | 37 (48.1)           | 48 (73.8)           |         |
| KPS             |                        |                     |                     |                     |         |
| 90–100          | 40 (19.5)              | 13 (20.6)           | 17 (22.1)           | 10 (15.4)           | 0.54    |
| 60–80           | 140 (68.3)             | 40 (63.5)           | 52 (67.5)           | 48 (73.8)           |         |
| Unknown*        | 25 (12.2)              | 10 (15.9)           | 8 (10.4)            | 7 (10.8)            |         |
| Comorbidity     |                        |                     |                     |                     |         |
| None to mild    | 93 (45.4)              | 28 (44.4)           | 40 (51.9)           | 25 (38.5)           | 0.27    |
| Moderate to severe | 112 (54.6)       | 35 (55.6)           | 37 (48.1)           | 40 (61.5)           |         |
| Current presentation |                  |                     |                     |                     |         |
| Primary presentation | 171 (83.4)       | 50 (79.4)           | 64 (83.1)           | 57 (87.7)           | 0.45    |
| Recurrent presentation | 34 (16.6)       | 13 (20.6)           | 13 (16.9)           | 8 (12.3)            |         |
| Symptoms at presentation** | | | | | |
| Dysphagia       |                        |                     |                     |                     |         |
| 0–1             | 77 (37.6)              | 21 (33.3)           | 26 (33.8)           | 30 (46.2)           | 0.25    |
| 2–4             | 126 (61.4)             | 41 (65.1)           | 50 (64.9)           | 35 (53.8)           |         |
| Unknown*        | 2 (1.0)                | 1 (1.6)             | 1 (1.3)             | 0 (0)               |         |
| Weight loss     |                        |                     |                     |                     |         |
| ≤5 kg           | 101 (50.2)             | 26 (41.3)           | 38 (49.4)           | 39 (59.0)           | 0.17    |
| >6 kg           | 89 (43.4)              | 33 (52.4)           | 33 (42.9)           | 23 (35.4)           |         |
| Unknown*        | 13 (6.3)               | 4 (6.3)             | 6 (7.8)             | 3 (4.6)             |         |
| Tube feeding before treatment | | | | | |
| No              | 159 (77.6)             | 52 (82.5)           | 55 (71.4)           | 52 (80.0)           | 0.18    |
| Yes             | 44 (21.5)              | 11 (17.5)           | 22 (26.8)           | 11 (16.9)           |         |
| Unknown*        | 2 (1.0)                | 0 (0)               | 0 (0)               | 2 (3.1)             |         |
| Tumour length   |                        |                     |                     |                     |         |
| ≤6 cm           | 119 (58.0)             | 32 (50.8)           | 38 (49.4)           | 49 (75.4)           | <0.01   |
| >6 cm           | 85 (41.5)              | 31 (49.2)           | 38 (49.4)           | 16 (24.6)           |         |
| Unknown*        | 1 (0.5)                | 0 (0)               | 1 (1.3)             | 0 (0)               |         |
| Tumour location |                        |                     |                     |                     |         |
| High – middle   | 39 (19.0)              | 6 (9.5)             | 18 (23.4)           | 15 (23.1)           | 0.27    |
| Low – GEJ       | 142 (69.3)             | 46 (73.0)           | 51 (66.2)           | 45 (69.2)           |         |
| Anastomosis     | 10 (4.9)               | 4 (6.3)             | 4 (5.2)             | 2 (3.1)             |         |
| Unknown*        | 14 (6.8)               | 7 (11.1)            | 4 (5.2)             | 3 (4.6)             |         |
| Histology       |                        |                     |                     |                     |         |
| Adenocarcinoma  | 120 (58.5)             | 40 (63.5)           | 48 (62.3)           | 32 (49.2)           | 0.03    |
| Squamous cell carcinoma  | 66 (32.2)       | 14 (22.2)           | 26 (33.8)           | 26 (40.0)           |         |
| Other           | 15 (7.3)               | 7 (11.1)            | 1 (1.3)             | 7 (10.8)            |         |
| Unknown*        | 4 (2.0)                | 2 (3.2)             | 2 (2.6)             | 0 (0)               |         |
| T stage         |                        |                     |                     |                     |         |
| T0–T3           | 61 (29.8)              | 15 (23.8)           | 21 (27.3)           | 25 (38.5)           | 0.99    |
| T4              | 28 (13.7)              | 7 (11.1)            | 10 (13.0)           | 11 (16.9)           |         |
| Unknown*        | 116 (56.6)             | 41 (65.1)           | 46 (59.7)           | 29 (44.6)           |         |
| N stage         |                        |                     |                     |                     |         |
| NO              | 31 (15.1)              | 4 (6.3)             | 5 (6.5)             | 22 (33.8)           | <0.01   |
| N+              | 147 (71.7)             | 49 (77.8)           | 62 (80.5)           | 36 (55.4)           |         |
| Unknown*        | 27 (13.2)              | 10 (15.9)           | 10 (13.0)           | 7 (10.8)            |         |
| M stage         |                        |                     |                     |                     |         |
| MO              | 69 (33.7)              | 7 (11.1)            | 15 (19.5)           | 47 (72.3)           | <0.01   |
| M1              | 125 (61.0)             | 51 (81.0)           | 61 (79.2)           | 13 (20.0)           |         |
| Unknown*        | 11 (5.4)               | 5 (7.9)             | 1 (1.3)             | 5 (7.7)             |         |

Abbreviations: EBRT, External beam radiotherapy; KPS, Karnofsky performance status; GEJ, Gastroesophageal junction.
* The ‘unknown’ categories were not included in calculation of p values.
** Total >100% due to possibility of having more than one symptom at presentation. Calculation p value not possible.
*** Dysphagia score as stated by Knyrim [23]: 0 = no dysphagia/able to eat normal diet, 1 = able to swallow some solid foods, 2 = able to swallow only semi solid foods, 3 = able to swallow liquids only, 4 = total dysphagia.
divided into three groups according to their intended EBRT schedule: 20 Gy in 5 fractions for 63 patients (of whom 4 patients were treated with 24 Gy in 6 fractions) (30.7%), 30 Gy in 10 fractions for 77 patients (37.6%) and 39 Gy in 13 fractions for 65 patients (31.7%) (Table 1).

Six patients, three in the 39 Gy and three in the 30 Gy group, stopped treatment prematurely (three on patient's request, one due to disease progression, two because of intercurrent disease). In one patient, treatment was interrupted due to hospitalization for COPD exacerbation, after which the patient resumed treatment and received one additional fraction for compensation. All patients were included in the analysis.

### 3.1. Patient characteristics

Patient characteristics are summarized in Table 1. Most patients had symptoms of dysphagia (89.8%, of whom 61.4% severe dysphagia (score 2-4)) and weight loss (72.7%). In the 20, 30 and 39 Gy group, respectively 47.6%, 48.1% and 73.8% of patients were over 70 years old (p = 0.002). Pathological lymph nodes were present in 77.8%, 80.5% and 55.4% in the 20 Gy, 30 Gy and 39 Gy group (p < 0.001). Distant metastasis at baseline were found in 81.0%, 79.2% and 20.0% in the 20 Gy, 30 Gy and 39 Gy group (p < 0.001).

Forty patients (19.5%) had undergone previous treatment for esophageal cancer; treatment with curative intent (chemoradiation...
and/or surgery) (N = 9 in 20 Gy, N = 13 in 30 Gy, N = 7 in 39 Gy group) or palliative chemotherapy (N = 9 in 20 Gy, N = 4 in 30 Gy, N = 2 in 39 Gy group).

3.2. Clinical response

Before treatment, 89.8% of patients had symptoms of dysphagia. A clinical response (improvement of dysphagia, relief of pain and/or reduction of esophageal bleeding) was experienced by 72.2% of patients without significant differences between the three groups (p = 0.45). During the first three months, dysphagia score improved at least one point in 41.0% of patients (47.6% in the 20 Gy, 40.3% in the 30 Gy and 35.4% in the 39 Gy group).

3.3. Toxicity

Frequent adverse events were fatigue, esophageal pain, esophagitis and nausea. Eight (3.9%) patients (N = 5 in the 20 Gy, N = 2 in the 30 Gy, N = 1 in the 39 Gy group) experienced an acute adverse effect of grade ≥ 3, in particular esophageal stenosis (N = 4), fatigue (N = 3), esophagitis (N = 1) or melena (N = 1). Four patients had severe pain requiring opioid medication. In total, 20.5% of patients had no acute toxicity reported in the charts. Occurrence of toxicity was unknown in 10.7% of patients.

3.4. Survival

Median OS for the whole group was 6.2 months (95%CI 4.8–7.6 months), with OS at one year and two years equal to 26.3 ± 3.1% and 6.2 ± 1.7% respectively. Kaplan-Meier curves for OS in the different treatment schedules are shown in Fig. 1 (p = 0.020 computed with the log rank test). Median OS in the 20 Gy, 30 Gy and 39 Gy groups was 4.6 months (95%CI 2.6–6.6), 5.2 months (95%CI 3.7–6.7) and 9.7 months (95%CI 6.9–12.5), respectively. At the last date of data entry for this study, eight patients were still alive, with a median follow-up time of 4.9 months (range 1.1 – 60.2 months). Two of these patients survived at least six years after treatment. Both patients had no distant metastasis and were treated with 39 Gy.

3.5. Univariate and multivariate analysis for overall survival

The univariate and multivariate analysis are shown in Table 2. In univariate analysis, treatment with the 39 Gy schedule showed a better OS compared to the 20 Gy schedule (HR 0.65 (95%CI 0.45–0.93)). Furthermore, in univariate analysis worse performance status (KPS), recurrent presentation of esophageal cancer, high dysphagia score, weight loss >6 kg, tumour length >6 cm, tube feeding before start of treatment, T stage and presence of distant metastasis were associated with worse OS. Patients older than 70 years showed a better OS in univariate analysis compared to patients aged 70 years or younger.

In the multivariate Cox regression model for OS the following prognostic factors were included: performance status (HR 2.25 (95%CI 1.53–3.29)), recurrent esophageal cancer (HR 1.69 (95%CI 1.15–2.47)), distant metastasis (HR 1.73 (95%CI 1.27–2.35)) and tumour length (HR 1.31 (95%CI 0.97–1.76)). Tumour length was statistically not significantly associated with OS, but was included in the final model because of significant association shown in previous literature [17]. Fig. 2 shows the estimated survival for the prognostic factors included in multivariate analysis.

3.6. Second intervention

In total, 50 (24.4%) patients underwent a second intervention for dysphagia. Thirty-three patients had a stent placement, and 21 patients received reirradiation with EBRT, mostly 20 Gy (N = 12) or 30 Gy (N = 8). Five patients were reirradiated with ILBT, with a dose of 12 Gy (N = 2), 10 Gy (N = 2) or 8 Gy (N = 1).

No second intervention was given to 95 (46.3%) patients, 60 (29.3%) patients were lost to follow up. Retreatment occurred in 22 patients (34.9%) of the 20 Gy group, 17 patients (22.1%) of the 30 Gy group and 11 patients (16.9%) of the 39 Gy group.

Treatment schedule was the only significant prognostic factor for time to second intervention, also after correction for possible confounding factors as tumour length, dysphagia score and histology. The adjusted cause specific hazard ratio was 0.50 (95%CI 0.25–0.99) and 0.27 (95%CI 0.13–0.56) for 30 and 39 Gy respectively (reference category 20 Gy). The cumulative incidence for time to second intervention is shown in Fig. 3. At six months, the cumulative incidence was 30.8% (95%CI 18.4–43.3), 18.2% (95%CI 7.7–28.6) and 4.1% (95%CI 0–9.8) in the 20 Gy, 30 Gy and 39 Gy treatment groups, respectively.

After the palliative EBRT, twenty-five patients (12.2%) were treated with chemotherapy (14 in the 20 Gy, 8 in the 30 Gy and 3 patients in the 39 Gy group).

4. Discussion

In our retrospective analysis investigating the effectiveness of EBRT for symptomatic esophageal cancer, a clinically significant improvement of symptoms was seen, with comparable outcomes in effect between 20, 30 and 39 Gy. Performance status, recurrent esophageal cancer, tumour length and distant metastasis were prognostic factors for overall survival. A longer time to second intervention was observed in patients treated with the 30 Gy or 39 Gy treatment schedule, compared to the 20 Gy schedule.

We found an improvement of symptoms in 72.2% of patients. Few studies examined the effect of EBRT alone [7,9,13,15]. Murray et al. [7] performed a retrospective analysis of 132 patients treated with 20 Gy in 5 fractions, finding a 75% improvement of dysphagia. Thirty-one patients treated with 40 Gy in 20 fractions with accelerated fractionation (two fractions a day) were analysed by Kassam...
These patients showed a dysphagia improvement of 69%. Homs et al. examined the effect of 12 Gy ILBT in 95 patients with inoperable esophageal carcinoma and found an improvement of 74% [6]. Thirty inoperable and previously irradiated patients with recurrent esophageal cancer, treated with 4-6 fractions of 5-7 Gy high-dose-rate ILBT, were evaluated by Wong Hee Kam et al [33]. After 1 month, complete response was found in 53%, with a median local progression-free survival of 9.8 months.

Most patients in our cohort experienced fatigue, esophageal pain, esophagitis or nausea, as seen in other studies as well [7,15]. Severe acute toxicity observed in our cohort is comparable to other literature [7,15]. In our 20 Gy group alone, a few more patients had severe adverse effects (7.9%) than patients in the other subgroups (2.6% and 1.5%) and the patients of Murray et al. (3%) [7]. Treatment with ILBT resulted in 12% of severe toxicity in Homs et al. [6].

We found a median OS of 6.2 months (95%CI 4.8–7.6) and a one year survival of 26.3% ± 3.1%. In the analysis of Murray et al. [7], median OS was 6.1 months, slightly better than the 20 Gy group in our cohort (4.6 months). This could be explained by the high percentage of distant metastasis in our treatment group (81.0%) compared to Murray et al. (28%). Albertsson et al. [13] found a median OS of 29 weeks and a one year survival of 22%, in patients treated with 24–45 Gy in fractions of 2 Gy. A median OS of 8 months was found in analysis by Kassam et al. [15]. The better survival observed by Kassam et al. could be related to the difference in exclusion criteria, the lower dysphagia score at baseline or the accelerated fractionation treatment. Homs et al. [6]...
examined the effect of 12 Gy ILBT and found a median OS of 155 days, comparable to our results.

Multivariate analysis revealed poor performance status, recurrent esophageal cancer and distant metastasis to be significant prognostic factors for worse OS. A tumour length of >6 cm was associated with worse OS. Three other studies investigated prognostic factors associated with OS in patients with incurable esophageal cancer, all proving distant metastasis to be significantly related to OS. In multivariate analysis by Homs et al. [6] and Steyerberg et al. [17], performance status was a prognostic factor as well, both using the WHO performance scale. Bergquist et al. [29] used the KPS, which was, in contrast to our study, only significant in the univariate analysis. A tumour length of >10 cm was a prognostic factor in the studies of Homs et al. and Steyerberg et al. as well. Dysphagia score was only significant in the univariate analysis, similar to Steyerberg et al.

In our cohort the 20 and 30 Gy groups only show a slight difference in OS, indicating that the pre-treatment estimation of survival in our daily clinical practice was not optimal. A predictive model for survival, as shown in previous literature [30], is important to prevent unnecessary long treatment schedules.

In total, 24.4% of patients in our cohort underwent a second intervention, compared to 44% treated with ILBT by Homs et al. [6]. Murray et al. observed a number of EBRT patients requiring a second intervention similar to our cohort [7]. After adjusting for possible confounders, patients treated with the 30 Gy or 39 Gy in our cohort experienced a longer time to second intervention. This might be due to the higher total dosage, suggesting a dose-response effect of EBRT as observed with ILBT in a recent review by Fuccio et al. [5]. However, as shown in a study on radiation of bone metastasis by Van der Linden et al. [34], choice of retreatment is possibly biased. Physicians were more willing to retreat patients after a short treatment schedule, because expectations of effectiveness were less and additional treatment stayed within limits of radiation tolerance. We did not investigate the effect of chemotherapy after palliative EBRT on symptom control. A recent RCT showed there was no statistically significant difference in dysphagia relief between chemoradiation and radiotherapy alone [35].

The main limitation of our cohort study is the retrospective design, which resulted in a high percentage of missing data, and the necessity to interpret patient-doctor communication on symptoms from the patient charts.

5. Conclusions

Our study shows that palliative EBRT provides good symptom control in the majority of patients with symptomatic esophageal cancer. A higher dose schedule was related to a longer time to second intervention. Hence, life expectancy is valuable in selecting the optimal treatment schedule to prevent an unnecessary long treatment and limit the chance of second intervention when life expectancy is longer.

Declarations of interest

None.

References

[1] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr; 2013 [accessed 23-11-2016].
[2] The Netherlands Cancer Registry. Incidence, Survival and Mortality Cancer Oesophagus. www.dutchcancerfigures.nl; 2017 [accessed 01-03-2017].
[3] Dai Y, Li C, Xie Y, Liu X, Zhang J, Zhou J, et al. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev 2014;10:Cd005048.
[4] Homs MY, Steyerberg EW, Eijkenboom WM, Tilanus HW, Stalpers LJ, Bartelsman JF, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004;364(9444):1497–504.
[5] Fuccio L, Mandolesi D, Farioli A, Hassan C, Frazioni L, Guido A, et al. Brachytherapy for the palliation of dysphagia owing to esophageal cancer: a systematic review and meta-analysis of prospective studies. Radiother Oncol 2017;122(3):312–9.
[6] Homs MY, Steyerberg EW, Eijkenboom WM, Siersema PD. Predictors of outcome of single-dose brachytherapy for the palliation of dysphagia from esophageal cancer. Brachytherapy 2006;5(1):41–8.
[7] Murray LJ, Din OS, Kumar VS, Dixon LM, Waddles JC. Palliative radiotherapy in patients with oesophageal carcinoma: a retrospective review. Pract Radiat Oncol 2012;2(4):257–64.
[8] Sharma V, Mahantshetty U, Dinshaw KA, Deshpande R, Sharma S. Palliation of advanced/recurrent esophageal carcinoma with high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2002;52(2):310–5.
[9] Welsch J, Kup PG, Nieder C, Khoraswipour V, Buhler H, Adamietz IA, et al. Survival and symptom relief after palliative radiotherapy for esophageal cancer. J Cancer 2016;7(2):125–30.
[10] Laskar SG, Lewis S, Agarwal JP, Mishra S, Mehta S, Patil P. Combined brachytherapy and external beam radiation: an effective approach for palliation in esophageal carcinoma. J Costemp Brachytherapy 2015;7(6):653–61.
[11] Rosenberg E, Jones G, Sur RK, Donde B, Salvajoli JV, Ghosh-Laskar S, et al. Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: a prospective multi-centre randomized trial of the International Atomic Energy Agency. Radiother Oncol 2010;97(3):488–94.
[12] Sur R, Donde B, Falkson C, Ahmed SN, Levin V, Nag S, et al. Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer. Brachytherapy 2004;3(4):191–5.
[13] Albertsson M, Ewers SB, Widmark H, Hambraeus G, Lillo-Gil R, Ranstam J. Evaluation of the palliative effect of radiotherapy for esophageal carcinoma. Acta Oncol 1989;28(2):267–70.
[14] Prasad NR, Kartihgeyan M, Vikram K, Partha sarathy R, Reddy KS. Palliative radiotherapy in esophageal cancer. Indian J Surg 2015;77(1):34–8.
[15] Kassam Z, Wong RK, Kingash J, Ung Y, Kamra J, DeBoer G, et al. A phase II/III study to evaluate the toxicity and efficacy of accelerated fractionation radiotherapy for the palliation of dysphagia from carcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 2008;20(1):53–60.
[16] Kelilokumpu-Lehtinen P, Huovinen R, Nikkanen V. Survival and esophageal passage after radiotherapy of inoperable esophageal carcinoma. A retrospective study of 106 cases. Acta Oncol 1990;29(2):175–8.
[17] Steyerberg EW, Homs MY, Stolvis A, Essink-Bot ML, Siersema PD. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc 2005;62(3):333–40.
[18] Harvey JA, Bessell JR, Beller E, Thomas J, Gottleby DC, Burmeister BH, et al. Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. Dis Esophagus 2004;17(3):260–5.
[19] van Ruler MA, Peters FP, Slingerland M, Ficco M, Grootenboers DA, Vulinj AK, et al. Clinical outcomes of definitive chemoradiation therapy using carboplatin and paclitaxel in esophageal cancer. Dis Esophagus 2017;30(4):1–9.

Fig. 3. Cumulative incidence of second intervention after palliative EBRT in patients with esophageal cancer.
